IP Library Granted Patent US 10,588,608
Granted Patent B2
US 10,588,608 · App. 15/680,430 · Granted Mar 17, 2020

Sampling systems and related materials and methods

Inventors: Mitchell Lawrence Jones (La Jolla, CA); Christopher Loren Wahl (La Jolla, CA); Aaron Olafur Laurence Philippsen (Victoria, CA); Nicholas David Allan (Victoria, CA); Mark Sasha Drlik (Victoria BC, CA); Ryan Paul McGuinness (Mill Valley, CA); Sharat Singh (Rancho Santa Fe, CA); Robert S. Magyar (Victoria, CA)
Assignee: Progenity, Inc.
A61B10/0045B01L3/50B01L3/5023B01L3/5085G01N1/405G01N33/56916G01N33/56938G01N33/56944A61B5/0071A61B5/14539A61B5/42A61B10/0038A61B10/02A61B2010/0061A61B2562/162B01L2200/0621B01L2200/0689B01L2200/141B01L2300/042B01L2300/069B01L2300/0636B01L2300/087B01L2300/088B01L2300/0832B01L2300/0877B01L2300/12B01L2300/1883B01L2400/0472B01L2400/0475B01L2400/0633B01L2400/0677
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,588,608
App. No.
15/680,430
Granted
Mar 17, 2020
Kind
B2
Abstract

Sampling systems that include an absorbent material a preservative, such as an analyte preservative, as well as related materials and methods, are disclosed.

Claims (42)

1. An ingestible device, comprising:

a sampling system, comprising:

a first absorbent member;

a second absorbent member different from the first absorbent member; and

at least one preservative,

wherein:

the first absorbent member is configured to absorb a fluid,

the sampling system is configured so that fluid that flows from an exterior of the ingestible device to an interior of the ingestible device enters the first absorbent member; and

the sampling system is configured to allow fluid to flow from the first absorbent member to the second absorbent member.

2. The ingestible device of claim 1 , wherein the at least one preservative is at least one analyte preservative.

3. The ingestible device of claim 2 , wherein the at least one analyte preservative comprises a preservative for at least one of a nucleic acid, a small molecule, or a protein.

4. The ingestible device of claim 2 , wherein the at least one analyte preservative comprises a preservative for at least one nucleic acid, small molecule, or protein that is a biomarker of at least one GI disorder.

5. The ingestible device of claim 2 , wherein the at least one analyte preservative is a surfactant.

6. The ingestible device of claim 2 , wherein the at least one analyte preservative is a stabilizer.

7. The ingestible device of claim 2 , wherein the at least one analyte preservative comprises a member selected from the group consisting of a nuclease inhibitor, an RNase inhibitor, and a protease inhibitor.

8. The ingestible device of claim 2 , wherein the at least one analyte preservative comprises an acid having a pKa of from three to seven.

9. The ingestible device of claim 2 , wherein the at least one analyte preservative comprises a paraben.

10. The ingestible device of claim 5 , wherein the surfactant comprises polysorbate.

11. The ingestible device of claim 6 , wherein the stabilizer comprises trehalose or dextran.

12. The ingestible device of claim 9 , wherein the paraben comprises a member selected from the group consisting of parahydroxybenzoate, an ester of parahydroxybenzoic acid, and propyl paraben.

13. The ingestible device of claim 7 , wherein the at least one analyte preservative comprises a protease inhibitor.

14. The ingestible device of claim 13 , wherein the protease inhibitor comprises a member selected from the group consisting of serine protease inhibitors, metalloprotease inhibitors, aminopeptidase inhibitors, cysteine peptidase inhibitor, and aspartyl protease inhibitors.

15. The ingestible device of claim 2 , wherein the at least one analyte preservative comprises an acid.

16. The ingestible device of claim 2 , wherein the at least one analyte preservative comprises at least one member selected from the group consisting of sorbic acid and citric acid.

17. The ingestible device of claim 1 , wherein the at least one preservative comprises at least one bacteria preservative.

18. The ingestible device of claim 17 , wherein the at least one bacteria preservative reduces bacterial growth and multiplication.

19. The ingestible device of claim 17 , wherein the at least one bacteria preservative comprises a bactericidal or bacteriostatic preservative.

20. The ingestible device of claim 17 , wherein the at least one bacteria preservative comprises a preservative for at least one bacterium associated with at least one GI disorder.

21. The ingestible device of claim 17 , wherein the at least one bacteria preservative comprises a member selected from the group consisting of sorbic acid, citric acid, propyl paraben, nisin, dimethyl dicarbonate, ethylenediaminetetraacetic acid (EDTA), sodium azide, hydroxyurea, fusidic acid, diazolidinyl urea, imidazolidinyl urea, salicylic acid, barium and nickle chloride, metallic copper, thimerosal, 2-phenoxyethanol, and ProClin.

22. The ingestible device of claim 17 , wherein the at least one bacteria preservative is sorbic acid, thimerosal, 2-phenoxyethanol, diazolinidyl urea, or imidazolinidyl urea.

23. The ingestible device of claim 2 , wherein the at least one absorbent member comprises at least one analyte preservative in addition to the at least one bacteria preservative.

24. The ingestible device of claim 23 , wherein the at least one analyte preservative is a nucleic acid preservative.

25. The ingestible device of claim 24 , wherein the nucleic acid preservative is a DNAse inhibitor or an RNase inhibitor.

26. The ingestible device of claim 1 , wherein the sampling system comprises a plurality of different preservatives.

27. The ingestible device of claim 1 , wherein the sampling system further comprises a cell filter between the first and second absorbent members.

28. The ingestible device of claim 1 , wherein the sampling system further comprises a cell filter.

29. The ingestible device of claim 1 , wherein the fluid comprises a GI fluid.

30. The ingestible device of claim 1 , wherein the sampling system is configured to fit within an ingestible device that does not include analytical instrumentation.

31. The ingestible device of claim 1 , wherein the at least one preservative is at least partially absorbed in the second absorbent member.

32. A method, comprising:

collecting a sample into the ingestible device of claim 1 .

33. The method of claim 32 , wherein the at least one preservative is at least partially absorbed in the second absorbent member.

Assignments (6)
SECURITY INTEREST Recorded Aug 15, 2025
From: BT BIDCO, INC.
To: GLAS USA LLC
Reel/Frame 072473/0861 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 20, 2025
From: BIORA THERAPEUTICS, INC.
To: BT BIDCO, INC.
Reel/Frame 070585/0061 →
LIEN Recorded Mar 18, 2025
From: BIORA THERAPEUTICS, INC.
To: BT BIDCO LLC
Reel/Frame 070552/0366 →
SECURITY INTEREST Recorded Dec 21, 2023
From: BIORA THERAPEUTICS, INC.
To: GLAS TRUST COMPANY LLC, AS COLLATERAL AGENT
Reel/Frame 066089/0235 →
CORRECTIVE ASSIGNMENT TO CORRECT THE NAME OF AARON OLAFUR LAURENCE PHILLIPPSEN PREVIOUSLY RECORDED ON REEL 048594 FRAME 0295. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Sep 16, 2019
From: JONES, MITCHELL LAWRENCE; WAHL, CHRISTOPHER LOREN; PHILIPPSEN, AARON OLAFUR LAURENCE; ALLAN, NICHOLAS DAVID; DRLIK, MARK SASHA; MCGUINNESS, RYAN PAUL; SINGH, SHARAT; MAGYAR, ROBERT S.
To: PROGENITY, INC.
Reel/Frame 050387/0834 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 14, 2019
From: JONES, MITCHELL LAWRENCE; WAHL, CHRISTOPHER LOREN; PHILIPPSEN, AARON LAURENCE OLAFUR; ALLAN, NICHOLAS DAVID; DRLIK, MARK SASHA; MCGUINNESS, RYAN PAUL; SINGH, SHARAT; MAGYAR, ROBERT S.
To: PROGENITY, INC.
Reel/Frame 048594/0295 →
Continuity (3)
Provisional Application 62545129 · Aug 14, 2017
Provisional Application 62376688 · Aug 18, 2016
Related Publication 20180052084A1 · Feb 22, 2018
Cited By (3)
US 12,446,794 US 12,582,809 US 12,653,992